| Entry |
|
|---|
| Name |
Trastuzumab deruxtecan (USAN/INN);
Trastuzumab deruxtecan (genetical recombination) (JAN);
Fam-trastuzumab deruxtecan-nxki;
Enhertu (TN) |
|---|
| Product |
|
|---|
| Formula |
C6460H9972N1724O2014S44. (C52H57FN9O13)8
|
|---|
| Exact mass |
153607.1079
|
|---|
| Mol weight |
153701.9811
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic |
|---|
| Disease |
Breast cancer (HER2 positive) [DS: H00031] |
|---|
| Comment |
Antibody-drug conjugate
|
|---|
| Target |
|
|---|
| Pathway |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC41 Trastuzumab deruxtecan
D11529 Trastuzumab deruxtecan (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11529 Trastuzumab deruxtecan (USAN/INN); Trastuzumab deruxtecan (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
D11529 Trastuzumab deruxtecan (USAN/INN) <JP/US>
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP1
D11529 Trastuzumab deruxtecan (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11529
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11529
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11529
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11529
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11529
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
